Fig. 3.
a Intrinsic subtype analysis. Exploratory analysis based on the subset of 21 genes from the PAM50 classifier available in our dataset for analysis, CTCs clustered with the more aggressive breast cancer subtypes (HER2 positive and luminal B) based on a 90 % confidence interval (p < 0.01) for assigning PAM50 subtype based on the available probes in the cDNA microarray. b As expected, CTCs derived from Stage IV patients had a higher risk of recurrence score in comparison to I-SPY1 primary tumors (most of which were high risk by a 70-gene classifier)